Feeley Kevin 4

What Happened
Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), had 7,197 restricted stock units (RSUs) settle into shares (no cash cost) on June 16, 2026. To satisfy tax withholding obligations tied to that settlement, he sold 3,729 shares in multiple open-market transactions on the same date for total proceeds of approximately $226,597. The RSU settlement/derivative conversion is reported at $0 per share.

Key Details

• Transaction date: June 16, 2026; Form 4 filed June 18, 2026.
• Sales: 760 shares @ $59.75 (proceeds $45,413); 2,106 shares @ $60.83 (proceeds $128,106); 863 shares @ $61.50 (proceeds $53,078). Total proceeds ≈ $226,597.
• RSU settlement: 7,197 RSUs converted to shares at $0 (no cash exercise cost). The filing also reports a derivative disposition related to the settlement.
• Shares owned after transaction: 39,954 shares of Class A common stock beneficially owned, plus RSUs representing rights to up to 82,043 additional shares and options to purchase up to 25,906 shares (per filing).
• Footnotes: Sales were a “sell-to-cover” to satisfy tax withholding (non-discretionary). Reported prices for the sale blocks are weighted averages with price ranges provided in the filing.
• Timeliness: Transaction dated 6/16 and Form 4 filed 6/18 — filed within the typical two-business-day window.

Context
This was a routine RSU settlement and sell-to-cover for tax withholding rather than an opportunistic open-market sale or a voluntary disposition. The RSUs settled without cash outlay (reported at $0), and a portion of the resulting shares were sold to meet tax obligations. Such sell-to-cover transactions are common and do not necessarily signal a change in insider sentiment.